Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: A randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 317, Issue 2, 2017, Pages 156-164

  Block, Geoffrey A ^a   Bushinsky, David A ^b   Cheng, Sunfa ^c   Cunningham, John ^d   Dehmel, Bastian ^c   Drueke, Tilman B ^e   Ketteler, Markus ^f   Kewalramani, Reshma ^c   Martin, Kevin J ^g   Moe, Sharon M ^h   Patel, Uptal D ⁱ   Silver, Justin ^j   Sun, Yan ^c   Wang, Hao ^c   Chertow, Glenn M ^k,l  

^a Denver Nephrology   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^f KLINIKUM COBURG   (Germany)

^g SAINT LOUIS UNIVERSITY   (United States)

^h INDIANA UNIVERSITY   (United States)

ⁱ DUKE UNIVERSITY   (United States)

^j HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^k STANFORD UNIVERSITY   (United States)

^l STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CINACALCET; ETELCALCETIDE; PARATHYROID HORMONE; AMG-416; BIOLOGICAL MARKER; CALCIMIMETIC AGENT; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; PEPTIDE;

ADULT; AGE; ANEMIA; ARTICLE; BRONCHITIS; CALCIUM BLOOD LEVEL; CANADA; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EUROPE; FEMALE; FOLLOW UP; HEADACHE; HEART FAILURE; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOTENSION; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; NEW ZEALAND; PARATHYROID HORMONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION; SECONDARY HYPERPARATHYROIDISM; SELF REPORT; SIDE EFFECT; UNITED STATES; VOMITING; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; HEMODIALYSIS; HYPERPARATHYROIDISM, SECONDARY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; TIME FACTOR;

ADMINISTRATION, ORAL; BIOMARKERS; CALCIMIMETIC AGENTS; CALCIUM; CINACALCET HYDROCHLORIDE; DOUBLE-BLIND METHOD; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAUSEA; PARATHYROID HORMONE; PEPTIDES; RENAL DIALYSIS; TIME FACTORS; VOMITING;

EID: 85010617566     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.19468     Document Type: Article

References (22)

1. Moe S, Drüeke T, Cunningham J, et al; Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-1953.
2. Tentori F, Wang M, Bieber BA, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: The DOPPS study. Clin J AmSoc Nephrol. 2015;10(1):98- 109.
3. Block GA, Bushinsky DA, Cunningham J, et al. Effect of etelcalcetide on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: Two randomized clinical trials. JAMA. doi:10.1001/jama.2016.19456.
4. Yusuf AA, Howell BL, Powers CA, St Peter WL. Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D. Am J Kidney Dis. 2014; 64(5):770-780.
5. Chertow GM, Block GA, Correa-Rotter R, et al. EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in undergoing dialysis. N Engl J Med. 2012;367:2482-2494.
6. Bushinsky DA, Block GA, Martin KJ, et al. Treatment of secondary hyperparathyriodism: Results of a phase 2 trial evaluating an intravenous peptide agonist of the calcium-sensing receptor. Am J Nephrol. 2015;42(5):379-388.
7. Koch GG. Comments on "Current issues in non-inferiority trials" by Thomas R. Fleming, Statistics in Medicine. Stat Med. 2008;27(3):333-342.
8. Walter S, Baruch A, Dong J, et al. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther. 2013; 346(2):229-240.
9. Chen P, Melhem M, Xiao J, Kuchimanchi M, Perez Ruixo JJ. Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis. J Clin Pharmacol. 2015;55(6):620-628.
10. Cozzolino M, Messa P, Brancaccio D, et al; FARO Study Group. Achievement of NKF/K-DOQI recommended target values for bone and mineral metabolism in incident hemodialysis patients: Results of the FARO-2 cohort. Blood Purif. 2014;38 (1):37-45.
11. Fernández-Martín JL, Martínez-Camblor P, Dionisi MP, et al; COSMOS group. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: The COSMOS study. Nephrol Dial Transplant. 2015;30 (9):1542-1551.
12. Moe SM, Abdalla S, Chertow GM, et al; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators. Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE trial. J AmSoc Nephrol. 2015;26(6):1466-1475.
13. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J AmSoc Nephrol. 2004;15(8):2208- 2218.
14. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis. 2006;47(1):149-156.
15. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370-1378.
16. Levin A, Rigatto C, Barrett B, et al; CanPREDDICT Investigators. Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort. Nephrol Dial Transplant. 2014;29(5):1037-1047.
17. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393-4408.
18. Poelzl G, Trenkler C, Kliebhan J, et al. FGF23 is associated with disease severity and prognosis in chronic heart failure. Eur J Clin Invest. 2014;44(12): 1150-1158.
19. Moe SM, Chertow GM, Parfrey PS, et al; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015;132(1):27-39.
20. Martin KJ, Bell G, Pickthorn K, et al. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol Dial Transplant. 2014;29(2): 385-392.
21. Martin KJ, Pickthorn K, Huang S, et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int. 2014; 85(1):191-197.
22. Wheeler DC, London GM, Parfrey PS, et al; EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial Investigators. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial. J AmHeart Assoc. 2014;3(6): E001363.